Okorafor Ugochi C, Okorafor Chiamaka I, Amadi Casmir, Onyinye Okam, Achime Nnanna
Cardiology, Meridian Cardiac Center, Lagos, NGA.
Pharmacy, Festac Primary Health Center, Amuwo-Odofin Local Government Area, Lagos, NGA.
Cureus. 2024 Sep 26;16(9):e70285. doi: 10.7759/cureus.70285. eCollection 2024 Sep.
Studies exploring the relationship between serum uric acid (sUA) and cardiovascular risk in the Nigerian population remain sparse. The study aimed to assess the association between sUA levels and two measures of cardiovascular risk, namely the Framingham 10-year Cardiovascular Risk Score (FRS) and the Atherogenic Index of Plasma (AIP).
This retrospective study used data from clinical records of new, previously unregistered patients presenting at a private cardiac hospital over one year from November 2022 to October 2023. In total, 428 patients presented newly to the hospital in that period. The records of 138 patients were included in the project after various exclusions were made including for incomplete anthropometric and laboratory data. Statistical tests of association were used to determine the significance of the relationship between sUA levels and the measures of cardiovascular risk. Two-tailed p <0.05 was deemed statistically significant.
Hyperuricemia was more prevalent in individuals with central obesity, i.e., waist circumference ≥94cm in males or 80cm in females (93.4% vs 6.6%; p=0.03). Serum uric acid also positively correlated with FRS (correlation coefficient: 0.190; p<0.05) and serum triglyceride levels and AIP (correlation coefficient: 0.259 and 0.294, respectively; p<0.001 for both). After multivariate analyses, uric acid was significantly and independently associated with high FRS and AIP after adjusting for age, smoking and diabetes history, blood pressure, total and high-density lipoprotein cholesterol, serum triglycerides and waist circumference (p<0.001).
The results emphasize the emergence of sUA as a pertinent cardiovascular risk factor in clinical settings. More research is needed to deduce the relationship, if any, between cardiovascular risk reduction and pharmacological reduction of sUA levels.
在尼日利亚人群中,探索血清尿酸(sUA)与心血管风险之间关系的研究仍然较少。本研究旨在评估sUA水平与两种心血管风险指标之间的关联,即弗雷明汉10年心血管风险评分(FRS)和血浆致动脉粥样硬化指数(AIP)。
这项回顾性研究使用了2022年11月至2023年10月期间在一家私立心脏病医院就诊的新的、以前未登记患者的临床记录数据。在此期间,共有428名患者首次到该医院就诊。在进行了各种排除后,包括因人体测量和实验室数据不完整等情况,138名患者的记录被纳入该项目。采用关联统计检验来确定sUA水平与心血管风险指标之间关系的显著性。双侧p<0.05被认为具有统计学显著性。
高尿酸血症在中心性肥胖个体中更为普遍,即男性腰围≥94cm或女性腰围≥80cm(93.4%对6.6%;p=0.03)。血清尿酸还与FRS呈正相关(相关系数:0.190;p<0.05),与血清甘油三酯水平和AIP也呈正相关(相关系数分别为0.259和0.294;两者p均<0.001)。多变量分析后,在调整了年龄、吸烟和糖尿病史、血压、总胆固醇和高密度脂蛋白胆固醇、血清甘油三酯及腰围后,尿酸与高FRS和AIP显著且独立相关(p<0.001)。
研究结果强调了sUA在临床环境中作为一个相关心血管危险因素的出现。需要更多研究来推断降低心血管风险与通过药物降低sUA水平之间是否存在关系。